Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GSK)
NYSE:GSK
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.15Last Year’s EPS
1.12Same Quarter Last Year
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 30, 2025
|% Change Since: -6.03%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in specialty medicines and promising R&D advancements, positioning GSK for continued success. However, challenges such as declining vaccine sales, macroeconomic uncertainties, and impacts from Medicare Part D redesign were notable concerns. Despite these issues, the overall sentiment remains positive due to strategic growth areas and confident long-term outlooks.Company Guidance
During GSK's Q1 2025 earnings call, the company reaffirmed its financial guidance for the year, reflecting strong performance and strategic advancements. Key metrics highlighted include a 4% increase in group sales, 5% growth in core operating profit, and 5% rise in core earnings per share to 44.9 pence. Specialty medicines drove sales growth with a 17% increase, whereas vaccine sales declined by 6% and general medicine sales remained stable. The company secured two out of the five FDA product approvals anticipated for 2025 and completed the acquisition of IDRX, enhancing its oncology pipeline. GSK generated over £1 billion in cash from operations, supporting its £2 billion share buyback program and increased dividend to 16 pence. The company maintained its trust goals, reaching an estimated 2 billion people with its vaccines and medicines over the past four years. Additionally, GSK confirmed its commitment to R&D productivity improvements and future growth opportunities, with 14 key pipeline opportunities expected to launch between 2025 and 2031, each having peak year sales potential of over £2 billion.Strong Sales and Earnings Growth
Group sales increased by 4%, core operating profit grew by 5%, and core earnings per share rose by 5% to 44.9 pence. Cash generated from operations was over £1 billion.
Specialty Medicines Performance
Specialty medicines, the largest business segment, grew by 17%, driven by contributions from respiratory immunology, oncology, and HIV.
Oncology Segment Growth
Oncology sales increased by 53%, with notable performances from Jemperli and AGILE, which more than doubled their sales.
HIV Treatment and Prevention Growth
HIV sales grew by 7%, driven by products like Dovato, Cabenuva, and Apretude, which saw growth of 19%, 38%, and 63% respectively.
R&D and Pipeline Progress
Two out of five expected FDA product approvals for 2025 have been secured. Promising assets like the ADC targeting B7H3 and the acquisition of IDRX enhance the oncology pipeline.
Positive Long-term Outlook
GSK remains confident in its medium and long-term growth prospects, with multiple product launches and FDA approvals anticipated in the coming years.
---
GSK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GSK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 30, 2025 | $38.97 | $39.85 | +2.26% |
| Feb 05, 2025 | $34.47 | $37.30 | +8.21% |
| Oct 30, 2024 | $37.36 | $36.22 | -3.05% |
| Jul 31, 2024 | $38.57 | $37.60 | -2.51% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does GlaxoSmithKline (GSK) report earnings?
GlaxoSmithKline (GSK) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is GlaxoSmithKline (GSK) earnings time?
GlaxoSmithKline (GSK) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GSK EPS forecast?
GSK EPS forecast for the fiscal quarter 2025 (Q2) is 1.15.
---
